이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bruker 관리

관리 기준 확인 4/4

Bruker's CEO는 Frank Laukien, Feb1991 에 임명되었습니다 의 임기는 33.33 년입니다. 총 연간 보상은 $ 5.86M, 15.8% 로 구성됩니다. 15.8% 급여 및 84.2% 보너스(회사 주식 및 옵션 포함). 는 $ 2.69B 가치에 해당하는 회사 주식의 26.58% 직접 소유합니다. 2.69B. 경영진과 이사회의 평균 재임 기간은 각각 10.2 년과 8.7 년입니다.

주요 정보

Frank Laukien

최고 경영자

US$5.9m

총 보상

CEO 급여 비율	15.8%
CEO 임기	33.4yrs
CEO 소유권	26.6%
경영진 평균 재임 기간	10.3yrs
이사회 평균 재임 기간	8.8yrs

최근 관리 업데이트

Recent updates

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Jun 09

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Apr 11

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Jan 22

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Jan 08

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Dec 26

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Nov 06

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Oct 23

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Sep 25

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Aug 09

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 27

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Jul 11

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Jun 26

Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Apr 25

These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well

Apr 07

Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth

Feb 20

Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching

Jan 17

CEO 보상 분석

Frank Laukien 의 보수는 Bruker 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$402m
Dec 31 2023	US$6m	US$926k	US$427m
Sep 30 2023	n/a	n/a	US$319m
Jun 30 2023	n/a	n/a	US$319m
Mar 31 2023	n/a	n/a	US$312m
Dec 31 2022	US$5m	US$873k	US$297m
Sep 30 2022	n/a	n/a	US$275m
Jun 30 2022	n/a	n/a	US$274m
Mar 31 2022	n/a	n/a	US$282m
Dec 31 2021	US$6m	US$812k	US$277m
Sep 30 2021	n/a	n/a	US$270m
Jun 30 2021	n/a	n/a	US$238m
Mar 31 2021	n/a	n/a	US$204m
Dec 31 2020	US$4m	US$689k	US$158m
Sep 30 2020	n/a	n/a	US$158m
Jun 30 2020	n/a	n/a	US$165m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$5m	US$753k	US$197m
Sep 30 2019	n/a	n/a	US$207m
Jun 30 2019	n/a	n/a	US$189m
Mar 31 2019	n/a	n/a	US$184m
Dec 31 2018	US$4m	US$731k	US$180m
Sep 30 2018	n/a	n/a	US$98m
Jun 30 2018	n/a	n/a	US$92m
Mar 31 2018	n/a	n/a	US$84m
Dec 31 2017	US$5m	US$704k	US$79m

보상 대 시장: Frank 의 총 보상 ($USD 5.86M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 13.50M ).

보상과 수익: Frank 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Frank Laukien (64 yo)

33.4yrs

테뉴어

US$5,858,761

보상

Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...

리더십 팀

이름	위치	테뉴어	보상	소유권
Frank Laukien	Chairman	33.4yrs	US$5.86m	26.58% $ 2.6b
Gerald Herman	Executive VP & CFO	6.3yrs	US$2.20m	0.028% $ 2.7m
Mark Munch	Corporate Executive VP and President of Bruker Nano Group & Corporate	9yrs	US$2.73m	0.046% $ 4.4m
Juergen Srega	President of Bruker CALID Group & Bruker Daltonics Division	11.5yrs	US$1.47m	0.076% $ 7.3m
Falko Busse	President of Bruker BioSpin Group	6.2yrs	US$1.35m	0.014% $ 1.4m
Justin Ward	Senior Director of Investor Relations & Corporate Development	no data	데이터 없음	데이터 없음
J. Alldredge	General Counsel & Secretary	no data	데이터 없음	데이터 없음
Burkhard Prause	President and CEO of Bruker Energy & Supercon Technologies	16.3yrs	US$967.91k	0.0074% $ 710.7k

10.3yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: BRKR 의 관리팀은 노련하고 경험 (평균 재직 기간 10.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Frank Laukien	Chairman	33.4yrs	US$5.86m	26.58% $ 2.6b
John Ornell	Independent Director	8.9yrs	US$241.01k	0.014% $ 1.3m
Robert Rosenthal	Independent Director	8.7yrs	US$224.01k	0.014% $ 1.3m
Richard Packer	Independent Director	17.2yrs	US$227.32k	0.047% $ 4.6m
William Linton	Independent Lead Director	24.4yrs	US$231.01k	0.022% $ 2.1m
Adelene Perkins	Independent Director	7.2yrs	US$224.01k	0.013% $ 1.2m
Hermann Requardt	Independent Director	8.9yrs	US$219.01k	0.014% $ 1.3m
Bonnie Anderson	Independent Director	3.8yrs	US$219.65k	0.0051% $ 488.6k
Cynthia Friend	Independent Director	8.2yrs	US$216.83k	0.0076% $ 738.7k
Philip Ma	Independent Director	2.3yrs	US$206.01k	0.0024% $ 228.9k

8.8yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: BRKR 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.

Bruker 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Bruker Corporation, Annual General Meeting, May 30, 2024

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Insider notifies of intention to sell stock

Chairman exercised options to buy US$3.4m worth of stock.

Insufficient new directors

Recent updates

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Bruker Corporation Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker: A Confusing Acquisition Spree

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

Bruker Corporation has completed a Follow-on Equity Offering.

First quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Dividend, Payable on June 17, 2024

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bruker Corporation Revises Earnings Guidance for the Year 2024

Now 23% undervalued after recent price drop

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Corporation: An Aggressive Acquisition Strategy

Bruker Corporation, Annual General Meeting, May 30, 2024

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Insider notifies of intention to sell stock

Fourth quarter dividend of US$0.05 announced

Consensus EPS estimates increase by 25%

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Price target increased by 14% to US$84.55

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Price target decreased by 11% to US$70.56

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman exercised options to buy US$3.4m worth of stock.

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Price target decreased by 8.7% to US$80.89

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Insufficient new directors

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Chairman notifies of intention to sell stock

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman exercised options to buy US$4.9m worth of stock.

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Bruker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Bruker Announces SciY Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

Bruker Corporation Announces New D6 PHASER Benchtop X-Ray Diffraction Platform for Materials Analysis and Advanced Research

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Executive VP & CFO recently sold US$1.1m worth of stock

Executive VP & CFO notifies of intention to sell stock